Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Prophylactic immunization is important for human immunodeficiency virus (HIV)-infected patients; however, there are insufficient data on the burden of vaccine-preventable diseases (VPDs), vaccination rates, and factors influencing vaccination. Materials and Methods: The incidence and prevalence of VPDs in HIV-infected patients between 2006 and 2017 were estimated using the Korean HIV/acquired immune deficiency syndrome (AIDS) cohort database. In addition, we evaluated the vaccination rates and influencing factors for vaccination in HIV-infected patients through multilevel analysis of clinico-epidemiological factors, immune status, and psychological status. A questionnaire survey was conducted among experts to determine whether they recommend vaccination for HIV-infected patients. Results: The incidence rates of hepatitis B virus (HBV) infection, herpes zoster, and anogenital warts were 1.74, 7.38, and 10.85 per 1,000 person-years, respectively. The prevalence of HBV infection and anogenital warts at enrollment was 4.8% and 8.6%, respectively, which increased to 5.3% and 12.0%, respectively, by 2017. In HIV-infected patients, HBV (21.7% in 2008, 56.3% in 2013, and 75.4% in 2017) and pneumococcal vaccination rates (3.0% in 2015, 7.6% in 2016, and 9.6% in 2017) increased annually, whereas the influenza vaccination rate remained similar by season (32.7 - 35.6%). In the multilevel analysis, peak HIV viral load (≥50 copies/mL: odds ratio [OR] = 0.64, 95% confidence interval [CI]: 0.44 - 0.93; reference, <50 copies/mL) was an influencing factor for pneumococcal vaccination, while nadir CD4 T-cell counts (200 - 350 cells/mm3: OR = 0.54, 95% CI: 0.38 - 0.76; <200 cells/mm3: OR = 0.89, 95% CI: 0.62 - 1.28; reference, ≥350 cells/mm3) was an influencing factor for HBV vaccination. Influenza vaccination was associated with male sex (OR = 1.94) and the number of antiretroviral therapy (ART) regimen change (OR = 1.16), but was not significantly associated with HIV viral load or CD4 T-cell counts. Most experts responded that they administer hepatitis A virus, HBV, pneumococcal, and influenza vaccines routinely, but not human papillomavirus (12.9%) or herpes zoster vaccines (27.1%). Conclusion: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.
Abstract
Background: Prophylactic immunization is important for human immunodeficiency virus (HIV)-infected patients; however, there are insufficient data on the burden of vaccine-preventable diseases (VPDs), vaccination rates, and factors influencing vaccination. Materials and Methods: The incidence and prevalence of VPDs in HIV-infected patients between 2006 and 2017 were estimated using the Korean HIV/acquired immune deficiency syndrome (AIDS) cohort database. In addition, we evaluated the vaccination rates and influencing factors for vaccination in HIV-infected patients through multilevel analysis of clinico-epidemiological factors, immune status, and psychological status. A questionnaire survey was conducted among experts to determine whether they recommend vaccination for HIV-infected patients. Results: The incidence rates of hepatitis B virus (HBV) infection, herpes zoster, and anogenital warts were 1.74, 7.38, and 10.85 per 1,000 person-years, respectively. The prevalence of HBV infection and anogenital warts at enrollment was 4.8% and 8.6%, respectively, which increased to 5.3% and 12.0%, respectively, by 2017. In HIV-infected patients, HBV (21.7% in 2008, 56.3% in 2013, and 75.4% in 2017) and pneumococcal vaccination rates (3.0% in 2015, 7.6% in 2016, and 9.6% in 2017) increased annually, whereas the influenza vaccination rate remained similar by season (32.7 - 35.6%). In the multilevel analysis, peak HIV viral load (≥50 copies/mL: odds ratio [OR] = 0.64, 95% confidence interval [CI]: 0.44 - 0.93; reference, <50 copies/mL) was an influencing factor for pneumococcal vaccination, while nadir CD4 T-cell counts (200 - 350 cells/mm3: OR = 0.54, 95% CI: 0.38 - 0.76; <200 cells/mm3: OR = 0.89, 95% CI: 0.62 - 1.28; reference, ≥350 cells/mm3) was an influencing factor for HBV vaccination. Influenza vaccination was associated with male sex (OR = 1.94) and the number of antiretroviral therapy (ART) regimen change (OR = 1.16), but was not significantly associated with HIV viral load or CD4 T-cell counts. Most experts responded that they administer hepatitis A virus, HBV, pneumococcal, and influenza vaccines routinely, but not human papillomavirus (12.9%) or herpes zoster vaccines (27.1%). Conclusion: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.
참고문헌 (14)
- Zhang D, "Clinical and economic burden of pneumococcal disease in US adults aged 19-64 years with chronic or immunocompromising diseases : an observational database study", BMC Infect Dis, 18, pp.436~ (2018)
- 대한에이즈학회, "국내 HIV 감염인의 기회감염증 치료와 예방에 관한 임상진료지침 권고안", Infection and Chemotherapy, 44(3), pp.93~139 (2012), 대한감염학회[DOI]
- Kerr C, "Changing demographics and immunity to vaccine preventable diseases in people with HIV in Ireland", BMC Infect Dis, 22, pp.582~ (2022)
- Zerdali E, "Hepatitis B virus prevalence, immunization and immune response in people living with HIV", AIDS in Istanbul, Turkey : a 21-year data analysis, 2021, pp.21, 1621~1628
- Bruzzesi E, "Prevalence and risk factors of anal HPV infection in MSM living with HIV : identifying the target groups to prioritize for immunization", J Acquir Immune Defic Syndr, 91, pp.226~231 (2022)
- Kolobova I, "Burden of vaccine-preventable diseases among at-risk adult populations in the US", Hum Vaccin Immunother, 18, pp.2054602~ (2022)
- Johnson TM, "Predictors of vaccination rates in people living with HIV followed at a specialty care clinic", Hum Vaccin Immunother, 17, pp.791~796 (2021)
- 최보율, "Korea HIV", AIDS Cohort Study: study design and baseline characteristics, 2018, pp.40, 1~8[DOI]
- 김유정, "Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study", Journal of Korean Medical Science, 34(2), pp.1~10 (2019), 대한의학회
- 임선영, "The epidemiology of hepatitis B virus infection in Korea", The Korean Journal of Internal Medicine, 34(5), pp.945~953 (2019), 대한내과학회[DOI]
- Lee TS, "A cross-sectional study estimating the burden of illness related to genital warts in South Korea", BMJ Open, 7, pp.e014217~ (2017)
- Buskin SE, "Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals", World J Gastroenterol, 17, pp.1807~1816 (2011)
- Patel H, "Systematic review of the incidence and prevalence of genital warts", BMC Infect Dis, 13, pp.39~ (2013)
- Imp BM, "Influenza vaccination uptake and associated factors among adults with and without human immunodeficiency virus in a large, integrated healthcare system", Clin Infect Dis, 77, pp.56~63 (2023)
